Sponsors (37)
The bill maintains and strengthens federal support for detecting and responding to vector‑borne diseases through 2030—protecting public health and program continuity—while increasing federal spending and slightly reducing stakeholder transparency about advisory roles.
Hospitals, state and local public health agencies will have increased capacity to identify, report, prevent, and respond to vector‑borne disease outbreaks because HHS programs are directed to strengthen surveillance, detection, and response capabilities.
State and local public health agencies — and the patients and communities they serve (including rural and chronic‑care patients) — will retain federal authorization and funding through 2030, reducing the risk of interruptions to surveillance and prevention programs.
Taxpayers may bear higher federal spending obligations to extend these authorizations through 2030, which could raise costs or crowd out other budget priorities.
State governments and the public may face reduced transparency about who advises HHS on tick‑borne disease policy because a specific stakeholder reference was replaced with a generic 'appropriate individuals' formulation.
Based on analysis of 1 section of legislative text.
Extends authorizations through 2026–2030, broadens stakeholder language, and adds capacity-building duties for vector-borne disease programs.
Official title: To reauthorize the Kay Hagan Tick Act, and for other purposes.
Introduced July 10, 2025 by Christopher Henry Smith · Last progress July 21, 2026
Extends existing authorizations for certain HHS programs addressing vector-borne and related diseases from 2026 through 2030, updates stakeholder wording to broaden eligible participants, and adds language directing capacity-building to improve identification, reporting, prevention, and response to such diseases. The amendments revise two Public Health Service Act provisions that support national vector-borne disease strategy, regional centers, and state and local health department assistance.